Novo Nordisk subsupplier reinitiates Wegovy production
According to Novo Nordisk, a contract manufacturer filling the syringes for Novo’s obesity drug Wegovy has once again started its commercial production.
by marketwire, translated by daniel pedersen
In connection with Novo Nordisk’s first quarterly report Friday morning, the company has announced that the contract manufacturer in charge of filling Wegovy doses, an obesity treatment currently available in the US, has reinitiated its commercial production.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk upgrades full-year guidance
For subscribers
